Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

Wyeth Pharmaceuticals (December 2008)

By the end of 2008 Santaris Pharma entered into an agreement with Wyeth Pharmaceuticals, covering 10 LNA-based drug candidates targeting various diseases selected by Wyeth. Under the terms of the collaboration Santaris Pharma will design and generate the drug compounds and Wyeth will be responsible for all preclinical- and clinical development as well as the commercialization on a worldwide basis.

GlaxoSmithKline Collaboration (December 2007)

Under the terms of the collaboration with GlaxoSmithKline (GSK) on new drugs for the treatment of viral diseases, Santaris Pharma is responsible for the discovery and development of RNA inhibiting drug candidates through to completion of Phase IIa ("Clinical Proof of Concept") for four viral targets, at which point GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialisation on a worldwide basis. Presently GSK has selected one viral disease target and Santaris Pharma has identified several strong drug candidates against the target.

Enzon Collaboration (August 2006)

Under the terms of the collaboration with Enzon Pharmaceuticals, Santaris Pharma will design and generate a total of eight drug candidates and Enzon will fund and manage the preclinical- and clinical development of the drug candidates and file for regulatory approvals outside Europe. Santaris Pharma has maintained all commercial rights for the eight drug candidates in Europe.

Enzon is expected to disclose final results from the clinical development of EZN/SPC2968, a HIF-1alpha inhibitor, which is currently being evaluated in two separate Phase I/II clinical trials in patients with advanced solid tumors, in the 2nd half of 2009.

Enzon has initiated a Phase I study in various solid tumors for EZN/SPC3042, the Survivin inhibitor, in the 1st quarter of 2009.


'/>"/>
SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
(Date:7/30/2014)... Sales Horizons, a leader in sales training ... programs for companies engaged in complex B2B sales. , ... of salespeople over 25 years in market-leading Fortune 500 ... customized to address the unique sales challenges of companies ... program consists of two parts: Mastering the Complex ...
(Date:7/30/2014)... EL SEGUNDO, Calif. , July 30, 2014 ... prime contractor on the Fully Integrated Lifecycle Mission ... Aeronautics and Space Administration (NASA). Under the terms ... to Ames Research Center at Moffett Field, Calif. ... management support for bioscience flight development projects on ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... Inc. (NYSE Alternext US: ILI) announced today, that on ... NYSE Alternext US LLC (the "the Exchange") indicating that ... of the Exchange,s continued listing standards under Section 1003 ... Company,s failure to comply with Section 1003(a)(iii) of the ...
... innate defence system against deadly bacteria. However, how the step ... not yet known. To date, B. Pseudomallei, a ... can remain hidden in the human body for many years ... suddenly become activated and spread throughout the body, resulting in ...
... Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of ... the broad anti-viral potential of the company,s novel ... drug bavituximab can cure lethal virus infections in ... in clinical trials for the treatment of hepatitis ...
Cached Biology Technology:Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii) 2Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii) 3Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3
(Date:7/30/2014)... announced an across-the-board increase in Impact Factors for ... Journal Citation Reports (Thomson Reuters, 2014) show that ... Essays in Biochemistry , Biochemical Society ... received increases in their Impact Factors. The journals ... by Portland Press Limited. , 2014 Impact Factors ...
(Date:7/30/2014)... to create colors, nature had already perfected the process ... hues, for example. Now scientists are tapping into those ... make colored plastics. Their paper on using structure ... than dyes, to produce color appears in the ACS ... Anders Kristensen and colleagues point out that currently, plastic ...
(Date:7/30/2014)... decisions about what they eat, the Food and Drug ... the Nutrition Facts label found on nearly every food ... & Engineering News (C&EN), the weekly news magazine ... and the fight that has ensued. , Britt ... while the Nutrition Facts label has remained largely the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2
... cattle feed as a possible culprit in the long-standing ... moderately-populated agricultural region has higher levels of ozone ... densely-populated cities. The report, which explains how fermented cattle ... in ACS, Environmental Science & Technology , a ...
... N.J. -- Stevens Institute of Technology presents Research & ... Arena , Schaefer Athletic Center on Stevens campus. ... including its array of startup companies and student based ... the Institutes, focus on entrepreneurship and success in engineering ...
... Virginia Tech biologist proposes to use a physics strategy called ... where they will be sensitive to antibiotics. In medicine, ... she thumps your chest. In physics, resonance is a periodic ... of a natural system,s frequency. Sound waves are an example ...
Cached Biology News:Research & Entrepreneurship Day 2010: Engineering Innovation 2Physics strategy tested as solution for antibiotic resistance 2
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
Biology Products: